Trial Profile
A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate-025
- Sponsors Bristol-Myers Squibb
- 07 Dec 2023 Results assessing whether PD-1 expression on intratumoral regulatory T cells is associated with lack of benefit from Anti-PD-1 therapy in metastatic clear cell renal cell carcinoma patients using multiparametric immunofluorescence in ccRCC tissues obtained from this study published in the Clinical Cancer Research
- 01 Dec 2023 This trial has been completed in Spain (Date of the global end of the trial: 19-Jul-2021), according to the European Clinical Trials Database record.
- 24 Oct 2023 Results assessing combined expression of MKI67, FOXC1 and PDL1 is a pan-tumor tissue-agnostic predictor of PD1/PDL1 inhibitor efficacy presented at the 48th European Society for Medical Oncology Congress